These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12428903)

  • 21. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target.
    Klibanov AL; Maruyama K; Beckerleg AM; Torchilin VP; Huang L
    Biochim Biophys Acta; 1991 Feb; 1062(2):142-8. PubMed ID: 2004104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice.
    Nässander UK; Steerenberg PA; Poppe H; Storm G; Poels LG; De Jong WH; Crommelin DJ
    Cancer Res; 1992 Feb; 52(3):646-53. PubMed ID: 1732053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.
    Manjappa AS; Goel PN; Gude RP; Ramachandra Murthy RS
    J Drug Target; 2014 Sep; 22(8):698-711. PubMed ID: 24766186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
    Sapra P; Moase EH; Ma J; Allen TM
    Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
    Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
    Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.
    Harding JA; Engbers CM; Newman MS; Goldstein NI; Zalipsky S
    Biochim Biophys Acta; 1997 Jul; 1327(2):181-92. PubMed ID: 9271260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification.
    Delgado C; Pedley RB; Herraez A; Boden R; Boden JA; Keep PA; Chester KA; Fisher D; Begent RH; Francis GE
    Br J Cancer; 1996 Jan; 73(2):175-82. PubMed ID: 8546903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells.
    Merdan T; Callahan J; Petersen H; Kunath K; Bakowsky U; Kopecková P; Kissel T; Kopecek J
    Bioconjug Chem; 2003; 14(5):989-96. PubMed ID: 13129403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PEG-liposome in DDS and clinical studies].
    Maruyama K
    Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes).
    Jin S; Li H; Xu Y
    Methods Mol Biol; 2023; 2622():197-205. PubMed ID: 36781762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells.
    Li T; Amari T; Semba K; Yamamoto T; Takeoka S
    Nanomedicine; 2017 Apr; 13(3):1219-1227. PubMed ID: 27965166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.
    Ding H; Carlton MM; Povoski SP; Milum K; Kumar K; Kothandaraman S; Hinkle GH; Colcher D; Brody R; Davis PD; Pokora A; Phelps M; Martin EW; Tweedle MF
    Bioconjug Chem; 2013 Nov; 24(11):1945-54. PubMed ID: 24175669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies.
    Hurwitz E; Klapper LN; Wilchek M; Yarden Y; Sela M
    Cancer Immunol Immunother; 2000 Jul; 49(4-5):226-34. PubMed ID: 10941905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
    Gao J; Zhong W; He J; Li H; Zhang H; Zhou G; Li B; Lu Y; Zou H; Kou G; Zhang D; Wang H; Guo Y; Zhong Y
    Int J Pharm; 2009 Jun; 374(1-2):145-52. PubMed ID: 19446771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
    Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
    Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of the antitumor activities of immunoconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers].
    Feng Y; Shao RG; Dai Y; Li BW; He HW; Ren KH
    Yao Xue Xue Bao; 2010 May; 45(5):571-5. PubMed ID: 20931757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation and biological evaluation of polymerizable antibody Fab' fragment targeted polymeric drug delivery system.
    Lu ZR; Shiah JG; Kopecková P; Kopecek J
    J Control Release; 2001 Jul; 74(1-3):263-8. PubMed ID: 11489505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases.
    Koning GA; Morselt HW; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
    Pharm Res; 2001 Sep; 18(9):1291-8. PubMed ID: 11683242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.